Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Catalyst Biosciences. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Catalyst Biosciences's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Catalyst Biosciences is high growth as no earnings estimate data is available.
Unable to determine if Catalyst Biosciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Catalyst Biosciences's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Catalyst Biosciences's finances.
The net worth of a company is the difference between its assets and liabilities.
Catalyst Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Catalyst Biosciences's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Catalyst Biosciences's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Catalyst Biosciences has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Nassim Usman, Ph.D. is a Venture Partner at Morgenthaler. Dr. Usman is a part of the life sciences team. He joined Morgenthaler as an Entrepreneur-in-Residence in 2005 and has also served as the Chief Executive Officer. He has been the Chief Executive Officer and President of Catalyst Biosciences, Inc. since August 2015. During his industrial career, He entered several drugs into clinical development, completed multiple licensing deals with pharmaceutical and biotechnology companies and raised capital in both private and public financings. Prior to joining Morgenthaler in 2005, he served as the Senior Vice President and Chief Operating Officer of Sirna Therapeutics, Inc. from December 23, 2003 to March 2005, its Vice President of Research and Development from August 2000 to December 23, 2003 and also its Chief Scientific Officer since February 2002. He served as the Senior Vice President of Research of Sirna Therapeutics Inc. from December 1999 to July 2000 and also as its Vice President of Research from May 1996 to December 1999. From April 1994 to May 1996, he served as the Director of Chemistry and Biochemistry Research and from September 1992 to April 1994. He served as a Senior Scientist of Chemistry and Biochemistry of Sirna Therapeutics Inc. He also held various research and development positions at both Sirna and Ribozyme Pharmaceuticals including Vice President of Research and Development and Chief Scientific Officer. He was a Venture Partner at Lightstone Ventures. Prior to joining Sirna Therapeutics Inc., he was a NIH Fogarty and NSERC Postdoctoral Fellow and Scientist in the Departments of Biology and Chemistry at the Massachusetts Institute of Technology from 1987 to 1992. He has been Director of Catalyst Biosciences, Inc. since August 2015. He serves as a Director at Osprey Pharmaceuticals USA, Inc., Mosaic Biosciences, Inc., Osprey Pharmaceuticals Limited . He serves as a Member of Advisory Board of Morgenthaler, CytRx Corporation. He served on the SABs of RXi Pharmaceuticals and Noxxon Pharma AG. He served as Member of Advisory Board of NOXXON Pharma AG. He served as a Director of Silence Therapeutics plc. He was a Director at Archemix Corp. and Atugen. He served as a Member of Scientific Advisory Board at Galena Biopharma, Inc. since April 9, 2007. In his doctoral dissertation, He developed a method for the solid-phase synthesis of RNA that is widely used in science and in a marketed RNA product. He has authored more than 70 scientific articles and 130 patents and applications. He holds a B.Sc. with honors and a Ph.D. in Organic Chemistry from McGill University. Dr. Usman was Director at Principia Biopharma Inc. until September 18, 2018.
Nassim's compensation has increased whilst company is loss making.
Nassim's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Catalyst Biosciences management team is about average.
Chief Financial Officer
Chief Medical Officer
Co-Founder & Chairman of Scientific Advisory Board
Senior Vice President of Technical Operations
Vice President of Business Development
Senior Director of Human Resources
Head of Clinical Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Catalyst Biosciences board of directors is about average.
Board of Directors
Chairman of the Board
Co-Founder & Chairman of Scientific Advisory Board
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors. The company is also developing Dalcinonacog alfa, a Factor IX drug, which has completed enrollment of a Phase I/II subcutaneous dosing trial for the prophylactic treatment of individuals with hemophilia B; CB 2679d-GT, a FIX gene therapy for the treatment of hemophilia B; and CB 2782, an anti-C3 protease program for the treatment of dry age-related macular degeneration (AMD), as well as CB 1965a, a Factor Xa therapeutic program used as a universal procoagulant. Catalyst Biosciences, Inc. has collaboration agreement with Pfizer, Inc. for the development of human Factor VIIa products; and ISU Abxis. The company has strategic research collaboration with Mosaic Biosciences, Inc. to develop intravitreal anti-complement factor 3 products for the treatment of dry AMD and other retinal diseases. The company was founded in 2002 and is headquartered in South San Francisco, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.